Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

thestreet.com — BOSTON (TheStreet) -- The December calendar of biotech and drug stock events. Food and Drug Administration approval decision to expand use of Incyte's Jakafi as a treatment for patients with polycythemia vera. Dec. 6-9 The American Society of Hematology annual meeting. This is the largest medical meeting focused on blood-related cancers like lymphoma and leukemia.

Ex-Retrophin CEO Shkreli Bought Company Stock Publicly While Selling Much More Under Cover

thestreet.com — NEW YORK ( TheStreet) -- In the weeks before his ouster as the CEO of Retrophin , Martin Shkreli was buying relatively small amounts of the company's shares on the open market and using his personal Twitter account to convince investors to do the same. "Not selling $RTRX.

Adam on Biotech Stocks

tumblr.com — An interesting side note from Monday's $840 million acquisition of Prosensa by BioMarin Pharmaceuticals: GlaxoSmithKline gave up rights to Prosensa's lead rare disease drug drisapersen in January 2014 because of negative results from a phase III study.

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing

thestreet.com — Stocks in this article: GALE Lincoln Park Financial set up a $55 million line of vulture financing for Galena Biopharma last week, the scandal-ridden bio-tech company still under active SEC investigation for paying outside firms to promote its stock while insiders made millions of dollars selling company shares.

BioMarin Acquires Prosensa in Deal Valued Up to $840 Million

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

thestreet.com — BOSTON ( TheStreet) -- This week's Biotech Stock Mailbag is open for business. @adamfeuerstein @JohnCFierce They took your advice and got a savvy health care investor and you still complain? Only beer can please you. - Benjamin Hodges (@BHodge14) November 20, 2014 "They" refers to Northwest Biotherapeutics , which raised another $35 million in two separate deals announced earlier this week.

Adam on Biotech Stocks

tumblr.com — I was waiting for that moment when my work writing about new drugs and my daughter's love of Japanese anime would cross over. Today's that day, thanks to Abbvie. From the creative geniuses deep inside Abbvie's marketing department comes brands names for the company's two, new hepatitis C drugs: Exviera Viekirax Drug name or Pokemon?

Royalty Pharma's $3.3 Billion Transaction is Bullish for Vertex Pharma

thestreet.com — Stocks in this article: VRTX The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.

Clovis Lung Cancer Update Swings Momentum to Rival, Slightly

thestreet.com — BOULDER, Col. ( TheStreet) -- Clovis Oncology and AstraZeneca are locked in a tight and very competitive race to develop two similar, targeted lung cancer drugs. Healthcare investors are watching closely, naturally. On Wednesday, a somewhat disappointing clinical update from Clovis swung momentum every so slightly in AstraZeneca's direction.

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells

thestreet.com — CAMBRIDGE, Mass. ( TheStreet) -- A second experimental drug from Agios Pharmaceuticals designed to attack the "metabolism" of cancer cells has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia. Of 14 patients with acute myeloid leukemia (AML) evaluable for response, seven patients achieved an objective response to treatment with four escalating doses of the Agios drug known as AG-120.
More Articles →
Nov 28, 2014

@buzz339 I wish him well but it’s not wise for me, or anyone, to recommend treatments. Your father should seek help at an academic med ctr.

Nov 28, 2014

@buzz339 That’s a serious question best answered by your doctor.

Nov 28, 2014

. @Sport234a I say, yes. $ACHN ‘3422 data Monday bc mgmt is speaking at Robyn K’s conference.

Nov 27, 2014

I should be charging you people for this musical Journey. Damn! pic.twitter.com/RPKjkqaQSB

Learn how to connect with Adam on social media by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile